TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
![TScan Therapeutics Logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/05/tscan-logo.png)
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, presented two posters and an oral presentation around TScan’s proprietary platform technologies for its solid tumor program at […]